title: Intravenous bisphosphonate-related osteonecrosis of the jaw: long-term follow-up of 109 patients.
abstract: OBJECTIVE
  We report long-term follow-up of patients with intravenous bisphosphonate-related osteonecrosis of the jaw (BRONJ).
  
  
  METHODS
  Medical and dental histories, including type and duration of bisphosphonate treatment and comorbidities, were analyzed and compared with clinical course of 109 patients with BRONJ at Memorial Sloan-Kettering Cancer Center Dental Service.
  
  
  RESULTS
  Median onset of BRONJ in months was 21 (zoledronic acid), 30 (pamidronate), and 36 (pamidronate plus zoledronic acid), with a significant difference between the pamidronate plus zoledronic acid and zoledronic acid groups (P = .01; Kruskal-Wallis). The median number of doses for BRONJ onset was significantly less with zoledronic acid (n = 18) than pamidronte plus zoledronic acid (n = 36; P = .001), but not pamidronate alone (n = 29). An association between diabetes (P = .05), decayed-missing-filled teeth (P = .02), and smoking (P = .03) and progression of BRONJ was identified through χ(2) test.
  
  
  CONCLUSIONS
  This long-term follow-up of BRONJ cases enhances the literature and contributes to the knowledge of BRONJ clinical course.
authors.affiliation: Dental Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
authors.forename: Amber L
authors.initials: AL
authors.lastname: Watters
authors.forename: Heidi J
authors.initials: HJ
authors.lastname: Hansen
authors.forename: Tijaana
authors.initials: T
authors.lastname: Williams
authors.forename: Joanne F
authors.initials: JF
authors.lastname: Chou
authors.forename: Elyn
authors.initials: E
authors.lastname: Riedel
authors.forename: Jerry
authors.initials: J
authors.lastname: Halpern
authors.forename: Steven
authors.initials: S
authors.lastname: Tunick
authors.forename: George
authors.initials: G
authors.lastname: Bohle
authors.forename: Joseph M
authors.initials: JM
authors.lastname: Huryn
authors.forename: Cherry L
authors.initials: CL
authors.lastname: Estilo
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw / Q000453:epidemiology*; D016009:Chi-Square Distribution; D015897:Comorbidity; D004245:DMF Index; D003920:Diabetes Mellitus / Q000453:epidemiology; D004164:Diphosphonates / Q000009:adverse effects*; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009519:New York City / Q000453:epidemiology; D000077268:Pamidronate; D012307:Risk Factors; D012907:Smoking / Q000453:epidemiology; D000077211:Zoledronic Acid
chemical_list: D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D000077268:Pamidronate